查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1853541

生物製藥第三方物流市場按服務類型、溫度範圍、運輸方式、最終用戶、產品類型和包裝類型分類－全球預測，2025-2032年

Biopharmaceutical Third Party Logistics Market by Service Type, Temperature Range, Mode Of Transportation, End User, Product Type, Packaging Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，生物製藥第三方物流市場規模將達到 3,642.3 億美元，複合年成長率為 14.67%。

關鍵市場統計數據
基準年 2024 1217.7億美元
預計年份：2025年 1400.3億美元
預測年份 2032 3642.3億美元
複合年成長率 (%) 14.67%

專業化的物流能力對於維護生物製藥產品的完整性以及促進其進入市場至關重要。

生物製藥的生命週期越來越依賴專業的第三方物流能力，以維護產品完整性、確保合規性並加快時間緊迫的交付。隨著先進療法、溫度敏感型生技藥品和複雜供應鏈的激增，相關人員必須應對由技術創新、監管和不斷變化的貿易動態所構成的複雜局面。

本報告綜合分析了物流物流及其客戶在科學研究、臨床和商業管道中的營運現狀和策略曲折點。報告探討了服務設計、溫度控制、運輸方式、包裝複雜性和終端用戶需求如何檢驗，從而影響營運重點。分析重點指出，供應商可以透過能力投資、流程標準化和風險規避來提升價值。

重要的是，本執行摘要旨在為高階領導提供簡潔而全面的觀點，以指導其採購、網路設計和夥伴關係策略。透過重點闡述最重要的趨勢和決策促進因素，本出版物旨在推動有針對性的投資，從而在不影響品質或合規性的前提下，減少產品損耗、加快患者獲取藥物的速度並降低總體成本。

讀者將獲得切實可行的見解，以支持供應鏈、品質、監管和商業團隊之間的跨職能協作，從而為物流相關人員在當今日益複雜的科學和監管環境中保持韌性和競爭力而必須做出的戰略選擇提供框架。

數位遙測、包裝創新、生產重新分配以及日益嚴格的監管要求如何重新定義物流供應商的策略重點

由於技術成熟、監管環境調整以及生產佈局變化，生物製藥第三方物流正經歷重大變革。數位化正從試點計劃走向營運核心，即時遠端檢測、基於狀態的異常管理和預測分析等技術能夠實現主動干預，從而減少藥品損耗並加快運輸速度。

同時，包裝創新正在重塑低溫運輸的經濟格局。主動隔熱包裝解決方案，例如氣調系統和先進的冷藏集裝箱，正擴大與先進的被動隔熱材料相結合，形成混合模式延長運輸窗口期並減少對加急運輸的依賴。這些技術進步與包裝設計和運輸規劃的緊密結合相輔相成，最佳化了有效載荷密度並降低了單件貨物的搬運風險。

另一個關鍵的轉型方向是製造和供應節點的策略性重新配置。區域製造地的加速成長以及生物製藥公司日益垂直化的趨勢，正迫使物流供應商重新配置其網路，轉向近岸外包和多節點配送。這種轉變需要靈活的倉儲佈局，既要具備常溫和冷藏倉儲能力，又要提供支援快遞空運、標準空運、海運和陸運等多種運輸方式的解決方案。

監管審查日益嚴格，合規要求也從文件準確性擴展到端到端管理，包括數位化審核追蹤和有效的溫度控制系統。因此，能夠展現出健全的品質系統、檢驗的流程和透明的監管鏈報告的供應商將贏得更高的信任度和市場青睞。簡而言之，產業正朝著一個以技術能力、監管應對力和網路適應性決定市場主導的生態系統發展。

評估 2025 年關稅調整如何刺激了對近岸外包、模式最佳化、海關專業知識增強以及整個生物製藥供應鏈韌性的投資。

2025年美國貿易政策帶來的關稅調整累積效應正顯著改變生物製藥供應鏈的跨國流動與策略物流決策。關稅導致的成本增加迫使許多製造商和物流合作夥伴重新評估籌資策略、庫存狀況和運輸方案，以在遵守關稅和貿易規則的同時維持利潤率和服務水準。

直接後果之一是近岸外包之爭愈演愈烈，各公司都在評估是否將部分生產過程轉移至更靠近關鍵市場的地方，或在關鍵市場附近儲備緩衝庫存，以減輕關稅導致的成本上漲的影響。這種戰術性轉變也對倉儲策略產生下游影響，要求倉儲策略具備靈活的合約條款以及在短時間內擴建冷藏和常溫倉庫的能力。

貿易壁壘也促使企業重新評估運輸方式。當關稅增加海運中間投入品或成品的到岸成本時，企業會透過將關鍵產品轉向高成本但速度更快的空運來減輕影響；或者，企業也會最佳化容器化策略，透過合併貨物數量來分攤關稅，從而降低成本。這兩種方法都需要加強包裝設計和運輸計畫之間的協調，以確保運輸過程中的溫度完整性，同時兼顧每次運輸的成本。

關稅調整加劇了海關流程的複雜性和文件審查的嚴格程度，凸顯了貿易合規專業知識在第三方物流中的重要性。能夠提供報關代理、關稅分類諮詢和關稅減免服務的供應商正日益獲得策略價值。此外，關稅波動也凸顯了合約中關於轉嫁成本、避險安排和服務水準調整條款的彈性的重要性。

除了成本管理之外，關稅也在加速企業對供應鏈視覺性和情境規劃的投資。如今，企業更加重視對分銷網路進行壓力測試，以應對不斷上漲的關稅，並模擬關稅對前置作業時間、庫存週轉天數和低溫運輸連續性等營運方面的影響。這種對韌性的關注也推動了對以分析主導的諮詢服務的需求，以及對雙重採購、緩衝倉儲和模組化運輸能力的投資，這些能力可以根據貿易動態的變化進行重新部署。

一個詳細的細分框架，揭示了服務類型、溫度範圍、運輸方式、最終用戶需求、產品類型和包裝選擇如何決定物流策略。

細分市場分析揭示了服務結構、溫度控制要求、運輸方式、終端用戶畫像、產品類型和包裝選項如何相互交織，從而定義物流供應商的價值提案和營運重點。從服務類型角度檢驗，市場涵蓋配送管理、包裝和貼標、運輸以及倉儲。包裝和貼標本身又分為主動式和被動式兩種方法，其中主動式包裝進一步細分為氣調包裝和冷藏集裝箱。運輸方式分為空運、鐵路運輸、公路運輸和海運，空運提供快遞和標準兩種選擇，以滿足不同的緊急程度和成本需求。倉儲業需要在常溫儲存和冷藏保管之間取得平衡，並且必須在經過檢驗的監控系統下運作。

溫度區域分類是一項核心營運決策，因為常溫、冷藏區、控溫區和冷凍區在處理、監控和監管要求方面各不相同。在冷藏區，又可區分監控冷藏環境和標準冷藏環境；控溫區也分為監控控溫和標準控溫；冷凍物流則分為標準製冷和超低溫要求，後者通常需要專門的基礎設施。

運輸方式細分揭示了空運、鐵路、道路運輸和海運的選擇如何影響運輸時間、環境影響和包裝需求。空運選項包括特快空運和標準空運，道路運輸區分整車運輸和零擔運輸模式，海運區分整箱運輸和拼箱運輸策略。這些運輸方式的差異體現在整個分銷網路的最佳包裝和庫存策略中。

生物製藥生產商、契約製造組織、受託研究機構、診斷實驗室以及醫院/診所各自對服務水準和監管要求各不相同。醫院和診所可細分為社區醫院和研究型醫院，它們的採購週期和臨床風險接受度也存在差異。

依產品類型細分，可以明確細胞療法、基因療法、單株抗體、重組蛋白和疫苗的獨特處理需求。細胞療法必須細分為樹突細胞療法和幹細胞療法，二者對低溫運輸的要求各不相同。疫苗分為去活化疫苗和減毒疫苗，二者在穩定性、運輸和監管要求上有差異。主動包裝包括冷藏貨櫃和溫控運輸箱，而被動包裝則使用保溫箱和保溫毯。這些細分維度共同構成了一個矩陣，該矩陣定義了第三方物流供應商的基礎設施投資、人員培訓和品質保證通訊協定。

美洲、歐洲、中東和非洲以及亞太地區的基礎設施、管理體制和商業動態將如何推動差異化的網路設計和服務優先順序的發展？

區域動態對網路設計和服務預期有顯著影響，每個區域都呈現不同的營運、監管和商業考量。在美洲，作為創新中心，先進的低溫運輸基礎設施和成熟的法規環境催生了對高頻快遞服務、高效冷藏倉庫和綜合海關服務的需求。區域貿易協定和國內製造業投資正在影響運輸方式的選擇和倉庫選址，而商業客戶則優先考慮關鍵治療藥物的快速補貨和可擴展的溫控倉庫。

歐洲、中東和非洲的情況各不相同。在西歐，嚴格的法律規範以及成熟的多式聯運路線促使供應商實施統一的品管系統和跨境低溫運輸解決方案。中東作為分銷和轉口樞紐，鼓勵投資建造以轉運為導向的倉庫和可靠的航空連接。在非洲，基礎設施和低溫運輸的挑戰凸顯了投資「最後一公里」解決方案、與當地產業營運商建立夥伴關係關係以及採用被動式包裝以彌補冷藏能力不足的重要性。

亞太地區融合了高產量製造中心、快速成長的區域需求以及多元化的法規環境。東南亞和南亞部分地區正在加速擴建常溫和冷藏倉庫，而東北亞則繼續推動對需要嚴格溫控和快速運輸的複雜生技藥品的出口。在全部區域，物流供應商必須平衡對大型低溫運輸資產的投資與能夠適應貿易流量、監管差異和季節性需求模式的靈活配送網路。

為什麼市場領導能夠透過結合數位化視覺性、完善的低溫運輸資產、監管專業知識以及靈活可擴展的商業模式而取得成功？

生物製藥第三方物流領域的主要企業在多個方面展現出差異化優勢，包括整合的數位化視覺性、檢驗的低溫運輸資產、法規和海關專業知識，以及能夠適應臨床和商業產品細微差別的靈活商業模式。市場領導者正在投資遠端檢測平台，以產生持續的狀態資料並實現自動化異常管理，同時不斷拓展地域佈局，將庫存部署在更靠近關鍵需求中心的位置。

策略夥伴關係和收購是快速獲取特定領域能力（例如超冷儲存或專業包裝和工程）的常用途徑。對於尋求降低風險的製造商和服務機構而言，能夠將內部技術專長與可擴展的倉儲規模和認證承運商網路結合的供應商極具提案。此外，將貿易合規和海關諮詢納入其服務組合的公司，能夠幫助企業應對複雜的跨境物流，從而創造更多價值。

卓越營運仍然是企業脫穎而出的關鍵。那些能夠跨區域標準化流程、檢驗包裝和運輸方案並維護嚴格文件記錄的公司，可以縮短監管檢查和審核期間的等待時間。物流供應商可以提供模組化服務，從專用冷藏庫到託管配送方案，從而滿足從委外研發機構到大型生物製藥生產商等各類組織的需求。最終，商業性成功與能否將技術能力轉化為可預測、審核的服務績效密切相關。

為物流領導者提供切實可行的、具有重大影響力的行動方案，以提高透明度、最佳化包裝策略、重新設計彈性網路，並將貿易合規性融入他們的服務產品中。

產業領導者應優先採取一系列切實可行的措施，為生物製藥產業建立一個穩健、合規且經濟高效的第三方物流能力。首先，投資建造一個端到端的視覺化系統，該系統能夠提供即時遠端檢測、自動異常警報和整合彙報功能，從而滿足營運需求和監管要求。這樣的系統可以減少產品損失，並在偏差時支援快速決策。

其次，採用結合被動和主動解決方案的多層包裝策略，在確保產品完整性的同時最佳化成本。透過根據運輸方式和溫度敏感性選擇合適的包裝，企業可以延長交貨期限，而無需總是依賴對時間要求嚴格的空運。這種方法應透過遵循主導通訊協定的合格測試進行檢驗。

第三，重新評估網路拓撲結構，並在適當情況下採用近岸外包或多節點分散部署。降低跨境風險，並將緩衝庫存放置在更靠近需求的位置，從而降低海關風險並縮短前置作業時間。但是，網路重新設計必須與服務提供者保持合約彈性，並制定應對容量限制的緊急時應對計畫。

第四，將貿易合規和海關諮詢服務整合到物流夥伴關係中，以便主動管理關稅影響和歸類風險。提供這些服務的供應商可以顯著減輕客戶的行政負擔，並提高到岸成本管理的可預測性。

最後，我們開發了一套模組化的商業服務方案，能夠快速實現從臨床到商業的擴展，滿足超低溫儲存需求，並為高風險產品類別提供專屬的客戶成功資源。將商業性獎勵與服務可靠性結合，有助於促進協作解決問題和建立長期夥伴關係。

採用嚴謹的混合方法研究途徑，結合從業者訪談、營運案例審查、選擇性二次綜合和專家交叉檢驗，以獲得實際的物流見解。

本分析所依據的研究採用了多種方法，結合了初步訪談、二手文獻綜述和營運案例分析，以確保研究結果的穩健性和有效性。初步研究包括對供應鏈和品質管理人員、物流人員、包裝工程師和監管專家進行結構化訪談，這些訪談有助於對能力差距和新興實踐進行定性評估。這些訪談構成了跨服務類型和區域的情境分析和風險映射的基礎。

為了闡明技術採納模式、監管發展和運輸方式成本動態，我們選擇性地參考了二手資料。透過對營運案例的分析，我們深入了解了包裝合格、低溫運輸故障和改進策略，從而能夠識別可複製的緩解措施和最佳實踐。我們優先考慮經過檢驗的案例，而非軼事，並參考多位獨立從業者的證詞來交叉驗證相關論點。

此分析方法嚴謹，包括對網路和包裝假設進行敏感度測試，以及由在生物製藥物流營運方面擁有實務經驗的專家進行同儕審查。該分析避免了推測性的預測，而是專注於經驗法則趨勢、觀察到的行為以及對採購和營運團隊的實際意義。

研究著重於定性和操作性洞察，而非專有的商業性指標。研究建議在適當情況下可根據具體情況進行調整，鼓勵各組織在進行大規模實施前進行局部檢驗和成本效益分析。

本文綜合闡述了經過檢驗的低溫運輸能力、適應性強的網路以及內建的貿易合規性為何能夠決定競爭優勢和營運韌性。

技術創新、監管趨嚴以及貿易格局的變化，共同加速了生物製藥第三方物流的發展。那些擁有先進遙測技術、檢驗的包裝生態系統以及深厚的監管和海關專業知識的先進包裝公司，最有可能滿足這個產品特性複雜、服務期望高的市場需求。在這種環境下，低溫運輸營運的卓越戰術性能夠直接轉化為製造商和醫療服務提供者的策略價值。

重新利用倉庫空間、調整運輸方式以及提供模組化服務包的能力，能夠幫助企業快速應對需求激增和政策變化。將貿易合規融入核心服務的企業，尤其是在關稅和跨境複雜性不斷湧現的情況下，將能夠減少摩擦並獲得競爭優勢。

最後，最成功的物流合作夥伴是那些實踐持續改善的合作夥伴。透過將洞察轉化為有效的流程和可衡量的績效，物流供應商可以減少浪費，加快患者獲得藥物的速度，並支持日益先進的生物製藥療法的更廣泛商業化途徑。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 推出人工智慧驅動的即時溫度監測解決方案，以確保低溫運輸物流過程中的生物穩定性
  • 擴建符合GDP標準的專用設施，以支援細胞和基因治療的儲存和分發需求
  • 運用數位雙胞胎技術進行建模，預測複雜生物製藥供應鏈中的中斷
  • 透過將第三方物流供應商與監管機構連接起來，簡化序列化和追蹤合規性流程
  • 建構集空運、海運和陸運於一體的多式聯運網路，以最佳化全球低溫運輸效率
  • 投資永續低溫運輸包裝解決方案，以減少碳排放並保持產品在遠距運輸過程中的完整性
  • 部署基於區塊鏈的平台，以提高生技藥品來源和溫度偏差追蹤的透明度
  • 對整合物聯網感測器和雲端分析技術的端到端可視性平台的需求日益成長，該平台可用於溫度敏感型貨物的運輸。
  • 針對mRNA疫苗分發，量身訂做的「最後一公里」配送策略夥伴關係，以滿足醫院和臨床試驗的需求。
  • 按需倉儲模式的成長為生物製藥分銷網路提供可擴展的容量和靈活的租賃條款

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 生物製藥第三方物流市場（依服務類型分類）

  • 分銷管理
  • 包裝和標籤
    • 活性包裝
      • CA包裝
      • 冷藏貨櫃
    • 標籤服務
    • 被動式封裝
  • 運輸
    • 空運
      • 航空快運
      • 標準航空公司
    • 鐵路運輸
    • 道路運輸
    • 海上運輸
  • 倉庫
    • 常溫倉庫存儲
    • 冷藏倉庫存儲

9. 生物製藥第三方物流市場（依溫度範圍分類）

  • 常溫
  • 冷藏
    • 用顯示器降溫
    • 標準冷藏
  • 恆溫
    • 恆溫監控器
    • 標準恆溫
  • 冷凍
    • 標準冷凍
    • 超級冷凍

第10章 生物製藥第三方物流市場（依運輸方式分類）

  • 空運
    • 航空快運
    • 標準航空公司
  • 鐵路貨運
  • 道路運輸
    • 整車運輸
    • 小批量卡車運輸
  • 海運
    • FCL
    • LCL

第11章 生物製藥第三會物流市場（以最終用戶分類）

  • 生物製藥製造商
  • CMO
  • CRO
  • 診斷實驗室
  • 醫院和診所
    • 社區醫院
    • 研究醫院

第12章 生物製藥第三方物流市場（依產品類型分類）

  • 細胞治療方法
    • 樹突細胞療法
    • 幹細胞療法
  • 基因治療
  • 單株抗體
  • 重組蛋白
  • 疫苗
    • 惰性
    • 活病毒疫苗

第13章 生技製藥第三方物流市場（依包裝類型分類）

  • 活性包裝
    • 冷藏貨櫃
    • 溫控運輸車
  • 被動式封裝
    • 保溫箱
    • 保溫毯

第14章 生物製藥第三會物流市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 生物製藥第三方物流市場（依產業分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國生物製藥第三方物流市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Kuehne+Nagel International AG
    • Deutsche Post AG
    • DSV Panalpina A/S
    • DB Schenker Logistics Germany AG & Co. KG
    • United Parcel Service, Inc.
    • FedEx Corporation
    • CEVA Logistics AG
    • Agility Public Warehousing Company KSCP
    • Bollore SE
    • Expeditors International of Washington, Inc.
Product Code: MRR-563BF1FCF7FA

The Biopharmaceutical Third Party Logistics Market is projected to grow by USD 364.23 billion at a CAGR of 14.67% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 121.77 billion
Estimated Year [2025] USD 140.03 billion
Forecast Year [2032] USD 364.23 billion
CAGR (%) 14.67%

An authoritative strategic overview highlighting why specialized logistics capabilities are mission-critical for preserving biopharmaceutical product integrity and enabling market access

The lifecycle of biopharmaceutical products increasingly depends on specialized third-party logistics capabilities that preserve integrity, ensure regulatory compliance, and expedite time-critical deliveries. As advanced therapies, temperature-sensitive biologics, and complex supply chains proliferate, stakeholders must navigate a landscape defined by technological innovation, regulatory scrutiny, and evolving trade dynamics.

This report synthesizes operational realities and strategic inflection points for logistics partners and their customers across research, clinical, and commercial channels. It examines how service design, temperature control, transportation modes, packaging sophistication, and end-user needs interact to shape operational priorities. The analysis highlights where providers can extract value through capability investment, process standardization, and risk mitigation.

Importantly, the executive summary is intended to equip senior leaders with a concise yet comprehensive perspective that informs procurement, network design, and partnership strategies. By foregrounding the most consequential trends and decision levers, this synthesis aims to catalyze targeted investments that reduce product loss, accelerate patient access, and improve total cost-to-serve without compromising quality or compliance.

Readers will find pragmatic insights that support cross-functional collaboration between supply chain, quality, regulatory, and commercial teams. The objective is to frame the strategic choices logistics stakeholders must make today to remain resilient and competitive in a sector where scientific and regulatory complexity continue to rise.

How digital telemetry, packaging innovation, manufacturing redistribution, and elevated regulatory expectations are collectively redefining strategic priorities for logistics providers

The biopharmaceutical third-party logistics landscape is undergoing transformative shifts driven by technological maturation, regulatory recalibration, and changing manufacturing footprints. Digitalization is moving beyond pilot projects into operational core functions, with real-time telemetry, condition-based exception management, and predictive analytics enabling proactive interventions that reduce spoilage and expedite shipments.

Simultaneously, packaging innovation is reshaping cold chain economics. Active packaging solutions such as controlled atmosphere systems and advanced refrigerated containers are increasingly deployed alongside sophisticated passive insulation to create hybrid models that extend viable transit windows and reduce reliance on expedited modes. These technical advances are complemented by tighter integration between packaging design and transportation planning, which together optimize payload density and lower per-unit handling risks.

Another key vector of transformation is the strategic redistribution of manufacturing and supply nodes. The acceleration of regional manufacturing hubs and increased verticalization among biopharmaceutical firms are prompting logistics providers to reconfigure networks toward nearshoring and multi-node distribution. These shifts require flexible warehousing footprints combining ambient and cold storage capabilities and tailored transportation solutions spanning express air, standard air, sea freight, and road modalities.

Regulatory scrutiny is intensifying, and compliance expectations are expanding from documentation accuracy to demonstrable end-to-end control through digital audit trails and validated temperature control systems. As a result, providers that can demonstrate robust quality systems, validated processes, and transparent chain-of-custody reporting will capture greater trust and market preference. In short, the industry is moving toward an ecosystem where technological capability, regulatory readiness, and network adaptability determine market leadership.

Assessing how 2025 tariff adjustments have triggered nearshoring, modal optimization, enhanced customs expertise, and resilience investments across biopharmaceutical supply chains

The cumulative effects of tariff adjustments originating from United States trade policy in 2025 are materially reshaping cross-border flows and strategic logistics decision-making for biopharmaceutical supply chains. Tariff-driven cost exposure has prompted many manufacturers and logistics partners to reassess sourcing strategies, inventory postures, and modal choices in order to preserve margin and service levels while maintaining compliance with customs and trade rules.

One immediate consequence is the intensification of nearshoring discussions. Companies are increasingly evaluating whether to relocate certain production steps or hold buffer inventories in closer proximity to key markets to reduce the incidence of tariff-triggered cost spikes. This tactical shift has downstream implications for warehousing strategies, requiring flexible contract terms and the ability to scale cold and ambient storage on short notice.

Trade barriers have also incentivized modal reassessment. When tariffs raise the landed cost of ocean-shipped intermediate inputs or finished goods, organizations may switch to higher-cost but faster air transport for critical SKUs to mitigate exposure, or conversely consolidate volumes and optimize containerization strategies to amortize duties over larger shipments. Both approaches demand enhanced coordination between packaging design and transportation planning to maintain temperature integrity while managing per-shipment economics.

Customs complexity and documentation scrutiny have increased in tandem with tariff changes, elevating the importance of trade compliance expertise within third-party logistics offerings. Providers that can deliver customs brokerage competence, tariff classification advisory, and duty mitigation services add strategic value. Moreover, tariff volatility has underscored the importance of contractual flexibility around pass-through costs, hedging arrangements, and service-level adjustment clauses so that commercial relationships remain equitable under shifting trade conditions.

Beyond cost management, tariffs have accelerated investments in supply chain visibility and scenario planning. Organizations now place greater emphasis on stress-testing distribution networks against tariff escalations and simulating their operational impact on lead times, inventory days of supply, and cold chain continuity. This greater focus on resilience translates into demand for analytics-driven consulting and a willingness to invest in dual-sourcing, buffer warehousing, and modular transportation capacity that can be redeployed as trade dynamics evolve.

A detailed segmentation framework exposing how service types, temperature classifications, transport modes, end-user demands, product categories, and packaging choices jointly determine logistics strategy

Segmentation analysis reveals how service structures, temperature control requirements, transportation modes, end-user profiles, product types, and packaging choices intersect to define value propositions and operational priorities for logistics providers. When examined through the lens of service type, the market encompasses distribution management, packaging and labeling, transportation, and warehousing. Packaging and labeling itself splits into active and passive approaches, with active packaging further differentiating into controlled atmosphere solutions and refrigerated containers. Transportation subdivides into air, rail, road, and sea, with air offering express and standard options that cater to different urgency and cost trade-offs. Warehousing balances ambient storage with cold storage capabilities that must operate under validated monitoring regimes.

Temperature range segmentation drives core operational decisions because ambient, chilled, controlled room temperature, and frozen conditions each impose distinct handling, monitoring, and regulatory requirements. The chilled segment distinguishes between monitored chilled and standard chilled environments, while controlled room temperature operations are similarly differentiated by monitored and standard variants; frozen logistics separates standard frozen from ultra-frozen requirements that often necessitate specialized infrastructure.

Mode-of-transportation segmentation highlights how choice of air freight, rail freight, road transport, and sea freight affects transit time, environmental exposure, and packaging demands. Air freight options include express and standard air, road transport distinguishes between full truck load and less-than-truckload models, and sea freight differentiates between full container load and less-than-container load strategies. These modal distinctions inform optimal packaging and inventory strategies across the distribution footprint.

End-user segmentation clarifies demand heterogeneity: biopharmaceutical manufacturers, contract manufacturing organizations, contract research organizations, diagnostic laboratories, and hospitals and clinics each generate different service-level expectations and regulatory touchpoints. Hospitals and clinics further split into community hospitals and research hospitals, which diverge in procurement cadence and clinical risk tolerance.

Product-type segmentation identifies unique handling needs across cell therapies, gene therapies, monoclonal antibodies, recombinant proteins, and vaccines. Cell therapies require sub-segmentation into dendritic cell therapies and stem cell therapies, each with intense cold chain sensitivity. Vaccines divide into inactivated and live attenuated types, which carry different stability, transport, and regulatory demands. Finally, packaging type segmentation contrasts active and passive systems; active packaging includes refrigerated containers and temperature-controlled shippers while passive solutions rely on insulated boxes and thermal blankets. Together, these segmentation axes form a matrix that governs infrastructure investment, personnel training, and quality assurance protocols for third-party logistics providers.

How distinct regional infrastructure, regulatory regimes, and commercial dynamics across the Americas, EMEA, and Asia-Pacific drive differentiated network design and service priorities

Regional dynamics materially influence network design and service expectations, with each geography presenting distinct operational, regulatory, and commercial considerations. In the Americas, dense innovation clusters, advanced cold chain infrastructure, and a mature regulatory environment create demand for high-frequency express services, validated cold storage, and integrated customs expertise. Regional trade agreements and domestic manufacturing investments shape modal choices and warehouse placement, while commercial customers prioritize rapid replenishment for critical therapies and scalable temperature-controlled warehousing.

Europe, the Middle East, and Africa present a heterogeneous set of conditions. Western Europe combines strict regulatory oversight with established multimodal corridors, encouraging providers to deploy harmonized quality management systems and cross-border cold chain solutions. The Middle East functions as a hub for distribution and re-export, prompting investments in transit-oriented warehousing and resilient air connectivity. Africa introduces infrastructural and cold chain challenges that increase the importance of last-mile solutions, partnership models with local operators, and investments in passive packaging to mitigate limited refrigerated capacity.

Asia-Pacific offers a blend of high-volume manufacturing centers, rapidly expanding regional demand, and variable regulatory environments. Southeast Asia and parts of South Asia are seeing accelerated capacity build-out for both ambient and cold storage, while Northeast Asia continues to drive high-complexity exports of biologics that demand rigorous temperature control and expedited transport options. Across the region, logistics providers must balance investment in large-scale cold chain assets with agile distribution networks that can adapt to fluctuating trade flows, regulatory differences, and seasonal demand patterns.

Why market leaders succeed through a combination of digital visibility, validated cold chain assets, regulatory expertise, and flexible, scalable commercial models

Leading companies in the third-party logistics space for biopharmaceuticals are differentiating along several axes: integrated digital visibility, validated cold chain assets, regulatory and customs expertise, and flexible commercial models that accommodate clinical and commercial product nuances. Market leaders invest in telemetry platforms that generate continuous condition data and enable automated exception management, while simultaneously expanding geographically to position inventory closer to key demand centers.

Strategic partnerships and acquisition activity are common routes to quickly acquire niche capabilities, such as ultra-low temperature storage or specialized packaging engineering. Providers that combine in-house technical know-how with scalable warehousing footprints and a network of certified carriers deliver a compelling proposition for manufacturers and service organizations seeking lower risk. In addition, firms that embed trade compliance and tariff advisory into their service mix provide additional value as companies navigate complex cross-border flows.

Operational excellence remains a differentiator: companies that standardize procedures across regions, validate packaging and transport solutions, and maintain rigorous documentation practices reduce latency during regulatory inspections and audits. The ability to offer modular services-from dedicated cold rooms to managed distribution programs-enables logistics providers to address the spectrum of needs from contract research organizations to large-scale biopharmaceutical manufacturers. Ultimately, commercial success correlates with the ability to translate technical capability into predictable, auditable service performance.

Practical, high-impact actions for logistics leaders to enhance visibility, optimize packaging strategies, redesign networks for resilience, and integrate trade compliance into service delivery

Industry leaders should prioritize a set of actionable steps to build resilient, compliant, and cost-effective third-party logistics capabilities for biopharmaceutical products. First, invest in end-to-end visibility systems that provide real-time telemetry, automated exception alerts, and integrated reporting to satisfy both operational needs and regulatory requirements. Such systems reduce product loss and support rapid decision-making when deviations occur.

Second, adopt a layered packaging strategy that pairs passive and active solutions to optimize cost while protecting product integrity. By aligning packaging selection with transit modality and temperature sensitivity, organizations can extend delivery windows without consistently resorting to time-critical air shipments. This approach should be validated through protocol-driven qualification testing.

Third, re-evaluate network topology to incorporate nearshoring and multi-node distribution where appropriate. Reducing cross-border exposure and situating buffer inventory closer to demand can mitigate tariff risk and shorten lead times. However, any network redesign must be accompanied by contractual flexibility with service providers and contingency plans for capacity constraints.

Fourth, embed trade compliance and customs advisory into logistics partnerships to proactively manage tariff implications and classification risks. Providers that offer these capabilities remove a significant administrative burden from customers and improve predictability in landed cost management.

Finally, develop modular commercial offerings that permit rapid scaling between clinical and commercial phases, support ultra-cold storage needs, and provide dedicated customer success resources for high-risk product classes. Aligning commercial incentives with service reliability encourages collaborative problem-solving and long-term partnerships.

A rigorous mixed-methods research approach combining practitioner interviews, operational case reviews, selective secondary synthesis, and expert peer validation to produce actionable logistics insights

The research underpinning this analysis combines a multi-method approach that triangulates primary interviews, secondary literature synthesis, and operational case reviews to ensure robustness and relevance. Primary inputs include structured interviews with supply chain and quality executives, logistics operators, packaging engineers, and regulatory specialists, which inform qualitative assessments of capability gaps and emergent practices. These conversations formed the basis for scenario analysis and risk mapping across service types and regions.

Secondary sources were selectively reviewed to contextualize technological adoption patterns, regulatory developments, and modal cost dynamics. Operational case reviews provided granular insight into packaging qualifications, cold chain failures, and remediation strategies, enabling the identification of repeatable mitigations and best practices. Emphasis was placed on validated examples rather than anecdote, and care was taken to cross-check claims against multiple independent practitioner accounts.

To maintain analytical rigor, the methodology incorporated sensitivity testing of network and packaging assumptions, as well as peer review by subject matter experts with hands-on experience in biopharma logistics operations. The analysis avoids speculative forecasts and focuses on empirically grounded trends, observed behaviors, and practical implications for procurement and operations teams.

Limitations are acknowledged: the research emphasizes qualitative and operational insights rather than proprietary commercial metrics. Where appropriate, recommendations are framed for adaptation to specific contexts and include prompts for organizations to conduct localized validation and cost-benefit analysis prior to large-scale implementation.

Synthesis of why validated cold chain capabilities, adaptable networks, and embedded trade compliance will determine competitive advantage and operational resilience

The confluence of technological innovation, regulatory tightening, and shifting trade dynamics is accelerating the evolution of third-party logistics for biopharmaceuticals. Providers that cultivate advanced telemetry, validated packaging ecosystems, and deep regulatory and customs expertise will be best positioned to serve a market defined by complex product sensitivity and high service expectations. In this environment, tactical excellence in cold chain operations translates directly into strategic value for manufacturers and care providers alike.

Network adaptability and commercial flexibility emerge as central themes: the ability to repurpose warehousing footprints, pivot transportation modes, and offer modular service packages enables rapid response to both demand surges and policy disruptions. Companies that integrate trade compliance into their core offering reduce friction and add competitive differentiation, especially as tariff volatility and cross-border complexity persist.

Finally, the most successful logistics partners will be those that operationalize continuous improvement-systematically validating packaging, stress-testing distribution designs, and investing in workforce training to meet rising quality expectations. By translating insights into validated processes and demonstrable performance, logistics providers can reduce waste, accelerate patient access, and support the broader commercialization pathways of increasingly sophisticated biopharmaceutical therapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of AI-driven real-time temperature monitoring solutions to ensure biologic stability during cold chain logistics
  • 5.2. Expansion of specialized GDP-compliant facilities to support cell and gene therapy storage and distribution requirements
  • 5.3. Implementation of digital twin technology for predictive modeling of complex biopharma supply chain disruptions
  • 5.4. Collaboration between 3PL providers and regulatory bodies to streamline serialization and track-and-trace compliance
  • 5.5. Development of multi-modal transportation networks integrating air, sea, and ground to optimize cold chain efficiency globally
  • 5.6. Investment in sustainable cold chain packaging solutions to reduce carbon footprint and maintain product integrity over long distances
  • 5.7. Adoption of blockchain-enabled platforms for enhanced transparency in biologics provenance and temperature excursion tracking
  • 5.8. Rising demand for end-to-end visibility platforms integrating IoT sensors and cloud analytics in temperature-sensitive shipments
  • 5.9. Strategic partnerships for last-mile delivery customized to hospital and clinical trial requirements in mRNA vaccine distribution
  • 5.10. Growth of on-demand warehousing models offering scalable capacity and flexible lease terms for biopharma distribution networks

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biopharmaceutical Third Party Logistics Market, by Service Type

  • 8.1. Distribution Management
  • 8.2. Packaging & Labeling
    • 8.2.1. Active Packaging
      • 8.2.1.1. Controlled Atmosphere Packaging
      • 8.2.1.2. Refrigerated Containers
    • 8.2.2. Labeling Services
    • 8.2.3. Passive Packaging
  • 8.3. Transportation
    • 8.3.1. Air Transport
      • 8.3.1.1. Express Air
      • 8.3.1.2. Standard Air
    • 8.3.2. Rail Transport
    • 8.3.3. Road Transport
    • 8.3.4. Sea Transport
  • 8.4. Warehousing
    • 8.4.1. Ambient Storage Warehousing
    • 8.4.2. Cold Storage Warehousing

9. Biopharmaceutical Third Party Logistics Market, by Temperature Range

  • 9.1. Ambient
  • 9.2. Chilled
    • 9.2.1. Monitored Chilled
    • 9.2.2. Standard Chilled
  • 9.3. Controlled Room Temperature
    • 9.3.1. Monitored Controlled Room Temperature
    • 9.3.2. Standard Controlled Room Temperature
  • 9.4. Frozen
    • 9.4.1. Standard Frozen
    • 9.4.2. Ultra Frozen

10. Biopharmaceutical Third Party Logistics Market, by Mode Of Transportation

  • 10.1. Air Freight
    • 10.1.1. Express Air
    • 10.1.2. Standard Air
  • 10.2. Rail Freight
  • 10.3. Road Transport
    • 10.3.1. Full Truck Load
    • 10.3.2. Less Than Truck Load
  • 10.4. Sea Freight
    • 10.4.1. Full Container Load
    • 10.4.2. Less Than Container Load

11. Biopharmaceutical Third Party Logistics Market, by End User

  • 11.1. Biopharmaceutical Manufacturers
  • 11.2. Contract Manufacturing Organizations
  • 11.3. Contract Research Organizations
  • 11.4. Diagnostic Laboratories
  • 11.5. Hospitals & Clinics
    • 11.5.1. Community Hospitals
    • 11.5.2. Research Hospitals

12. Biopharmaceutical Third Party Logistics Market, by Product Type

  • 12.1. Cell Therapies
    • 12.1.1. Dendritic Cell Therapies
    • 12.1.2. Stem Cell Therapies
  • 12.2. Gene Therapies
  • 12.3. Monoclonal Antibodies
  • 12.4. Recombinant Proteins
  • 12.5. Vaccines
    • 12.5.1. Inactivated
    • 12.5.2. Live Attenuated

13. Biopharmaceutical Third Party Logistics Market, by Packaging Type

  • 13.1. Active Packaging
    • 13.1.1. Refrigerated Containers
    • 13.1.2. Temperature Controlled Shippers
  • 13.2. Passive Packaging
    • 13.2.1. Insulated Boxes
    • 13.2.2. Thermal Blankets

14. Biopharmaceutical Third Party Logistics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Biopharmaceutical Third Party Logistics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Biopharmaceutical Third Party Logistics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Kuehne + Nagel International AG
    • 17.3.2. Deutsche Post AG
    • 17.3.3. DSV Panalpina A/S
    • 17.3.4. DB Schenker Logistics Germany AG & Co. KG
    • 17.3.5. United Parcel Service, Inc.
    • 17.3.6. FedEx Corporation
    • 17.3.7. CEVA Logistics AG
    • 17.3.8. Agility Public Warehousing Company K.S.C.P.
    • 17.3.9. Bollore SE
    • 17.3.10. Expeditors International of Washington, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TEMPERATURE RANGE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TEMPERATURE RANGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MODE OF TRANSPORTATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MODE OF TRANSPORTATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY DISTRIBUTION MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY DISTRIBUTION MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY DISTRIBUTION MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY DISTRIBUTION MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY DISTRIBUTION MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY DISTRIBUTION MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING & LABELING, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING & LABELING, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING & LABELING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING & LABELING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING & LABELING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING & LABELING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING & LABELING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PACKAGING & LABELING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ACTIVE PACKAGING, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ACTIVE PACKAGING, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ACTIVE PACKAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ACTIVE PACKAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ACTIVE PACKAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ACTIVE PACKAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ACTIVE PACKAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ACTIVE PACKAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ATMOSPHERE PACKAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ATMOSPHERE PACKAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ATMOSPHERE PACKAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ATMOSPHERE PACKAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ATMOSPHERE PACKAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ATMOSPHERE PACKAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY REFRIGERATED CONTAINERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY REFRIGERATED CONTAINERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY REFRIGERATED CONTAINERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY REFRIGERATED CONTAINERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY REFRIGERATED CONTAINERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY REFRIGERATED CONTAINERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LABELING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LABELING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LABELING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LABELING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LABELING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LABELING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PASSIVE PACKAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PASSIVE PACKAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PASSIVE PACKAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PASSIVE PACKAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PASSIVE PACKAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY PASSIVE PACKAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TRANSPORTATION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TRANSPORTATION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TRANSPORTATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TRANSPORTATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TRANSPORTATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TRANSPORTATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TRANSPORTATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TRANSPORTATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR TRANSPORT, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR TRANSPORT, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR TRANSPORT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR TRANSPORT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR TRANSPORT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR TRANSPORT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR TRANSPORT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR TRANSPORT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY EXPRESS AIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY EXPRESS AIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY EXPRESS AIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY EXPRESS AIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY EXPRESS AIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY EXPRESS AIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD AIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD AIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD AIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD AIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD AIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD AIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY RAIL TRANSPORT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY RAIL TRANSPORT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY RAIL TRANSPORT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY RAIL TRANSPORT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY RAIL TRANSPORT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY RAIL TRANSPORT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ROAD TRANSPORT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ROAD TRANSPORT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ROAD TRANSPORT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ROAD TRANSPORT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ROAD TRANSPORT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ROAD TRANSPORT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SEA TRANSPORT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SEA TRANSPORT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SEA TRANSPORT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SEA TRANSPORT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SEA TRANSPORT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SEA TRANSPORT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY WAREHOUSING, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY WAREHOUSING, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY WAREHOUSING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY WAREHOUSING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY WAREHOUSING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY WAREHOUSING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY WAREHOUSING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY WAREHOUSING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AMBIENT STORAGE WAREHOUSING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AMBIENT STORAGE WAREHOUSING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AMBIENT STORAGE WAREHOUSING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AMBIENT STORAGE WAREHOUSING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AMBIENT STORAGE WAREHOUSING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AMBIENT STORAGE WAREHOUSING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COLD STORAGE WAREHOUSING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COLD STORAGE WAREHOUSING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COLD STORAGE WAREHOUSING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COLD STORAGE WAREHOUSING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COLD STORAGE WAREHOUSING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY COLD STORAGE WAREHOUSING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TEMPERATURE RANGE, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY TEMPERATURE RANGE, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AMBIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AMBIENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AMBIENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AMBIENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AMBIENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AMBIENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CHILLED, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CHILLED, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CHILLED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CHILLED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CHILLED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CHILLED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CHILLED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CHILLED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MONITORED CHILLED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MONITORED CHILLED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MONITORED CHILLED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MONITORED CHILLED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MONITORED CHILLED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MONITORED CHILLED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD CHILLED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD CHILLED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD CHILLED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD CHILLED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD CHILLED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD CHILLED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ROOM TEMPERATURE, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ROOM TEMPERATURE, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ROOM TEMPERATURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ROOM TEMPERATURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ROOM TEMPERATURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ROOM TEMPERATURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ROOM TEMPERATURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY CONTROLLED ROOM TEMPERATURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MONITORED CONTROLLED ROOM TEMPERATURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MONITORED CONTROLLED ROOM TEMPERATURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MONITORED CONTROLLED ROOM TEMPERATURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MONITORED CONTROLLED ROOM TEMPERATURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MONITORED CONTROLLED ROOM TEMPERATURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MONITORED CONTROLLED ROOM TEMPERATURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD CONTROLLED ROOM TEMPERATURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD CONTROLLED ROOM TEMPERATURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD CONTROLLED ROOM TEMPERATURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD CONTROLLED ROOM TEMPERATURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD CONTROLLED ROOM TEMPERATURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD CONTROLLED ROOM TEMPERATURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FROZEN, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FROZEN, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FROZEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FROZEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FROZEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FROZEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FROZEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FROZEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD FROZEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD FROZEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD FROZEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD FROZEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD FROZEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD FROZEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ULTRA FROZEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ULTRA FROZEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ULTRA FROZEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ULTRA FROZEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ULTRA FROZEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ULTRA FROZEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MODE OF TRANSPORTATION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY MODE OF TRANSPORTATION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR FREIGHT, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR FREIGHT, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR FREIGHT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR FREIGHT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR FREIGHT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR FREIGHT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR FREIGHT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY AIR FREIGHT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY EXPRESS AIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY EXPRESS AIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY EXPRESS AIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY EXPRESS AIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY EXPRESS AIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY EXPRESS AIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD AIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD AIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD AIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD AIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD AIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY STANDARD AIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY RAIL FREIGHT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY RAIL FREIGHT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY RAIL FREIGHT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY RAIL FREIGHT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY RAIL FREIGHT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY RAIL FREIGHT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ROAD TRANSPORT, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ROAD TRANSPORT, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ROAD TRANSPORT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ROAD TRANSPORT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ROAD TRANSPORT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ROAD TRANSPORT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ROAD TRANSPORT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY ROAD TRANSPORT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FULL TRUCK LOAD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FULL TRUCK LOAD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FULL TRUCK LOAD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FULL TRUCK LOAD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FULL TRUCK LOAD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FULL TRUCK LOAD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LESS THAN TRUCK LOAD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LESS THAN TRUCK LOAD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LESS THAN TRUCK LOAD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LESS THAN TRUCK LOAD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LESS THAN TRUCK LOAD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LESS THAN TRUCK LOAD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SEA FREIGHT, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SEA FREIGHT, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SEA FREIGHT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SEA FREIGHT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SEA FREIGHT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SEA FREIGHT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SEA FREIGHT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY SEA FREIGHT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FULL CONTAINER LOAD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FULL CONTAINER LOAD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FULL CONTAINER LOAD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FULL CONTAINER LOAD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FULL CONTAINER LOAD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY FULL CONTAINER LOAD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LESS THAN CONTAINER LOAD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LESS THAN CONTAINER LOAD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LESS THAN CONTAINER LOAD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LESS THAN CONTAINER LOAD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LESS THAN CONTAINER LOAD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY LESS THAN CONTAINER LOAD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY BIOPHARMACEUTICAL MANUFACTURERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY BIOPHARMACEUTICAL MANUFACTURERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY BIOPHARMACEUTICAL MANUFACTURERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY BIOPHARMACEUTICAL MANUFACTURERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL BIOPHARMACEUTICAL THIRD PARTY LOGISTICS MARKET SIZE, BY BIOPHARMACEUTICAL MANUFACTURERS, BY COUNTRY, 2018-2024 (USD MILLION)

T